Because the altered expression of the SMAD1/S1PR2 and IRE1/XBP1s pathways could contribute to malignant progression of CLL, we tested whether they could be targeted together to deliver enhanced cytotoxicity against CLL. Here, SMAD1 is linked to B-cell chronic lymphocytic leukemia.